Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSERT: Infliximab in Ankylosing Spondylitis
NCT00207701Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2002
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Placebo -> Infliximab with Infliximab (2 arms). Primary endpoint: Assessment in Ankylosing Spondylitis Response Criteria 20 at 24 weeks. Started Sep 2002; status: completed.
02
Drugs
infliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00207701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00207701.